S. Durland-Busbice

Abstract A108: LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents.

T. Burke, R. Beckmann, M. Marshall, 2011 .

Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

A. Dantzig, R. Shepard, G. Donoho, 2013, Molecular Cancer Therapeutics.

Lack of p53 expression in human myeloid leukemias is not due to mutations in transcriptional regulatory regions of the gene

D. Reisman, S. Durland-Busbice, 2002, Leukemia.

Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells

Philip W. Iversen, Robert L. Shepard, P. Iversen, 2013, Clinical Cancer Research.

Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells

P. Iversen, A. Dantzig, R. Shepard, 2013, Clinical Cancer Research.